3-Methylpyrido<3,2-c>pyridazin | 72425-37-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 3-Methylpyrido<3,2-c>pyridazin
• 英文别名: 3-methyl-pyrido[3,2-c]pyridazine；Ztgsnxdkrjisqn-uhfffaoysa-；3-methylpyrido[3,2-c]pyridazine
• CAS: 72425-37-7
• 化学式: C₈H₇N₃
• 分子量: 145.164
• InChiKey: ZTGSNXDKRJISQN-UHFFFAOYSA-N

物化性质

• 沸点：
  296.3±32.0 °C(Predicted)
• 密度：
  1.214±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  38.7
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  3-methyl-3,4-dihydro-pyrido[3,2-c]pyridazine-1,2-dicarboxylic acid di-tert-butyl ester 、 三氟乙酸 以38%的产率得到
  参考文献：
  名称：

  JONES G.; RAFFERTY P., TETRAHEDRON, 1979, 35, NO 17, 2027-2033

  摘要：

  DOI：

文献信息

• SILICON BASED DRUG CONJUGATES AND METHODS OF USING SAME
  申请人：BlinkBio, Inc.

  公开号：US20170202970A1

  公开（公告）日：2017-07-20

  Described herein are silicon based conjugates capable of delivering one or more payload moieties to a target cell or tissue. Contemplated conjugates may include a silicon-heteroatom core, one or more optional catalytic moieties, a targeting moiety that permits accumulation of the conjugate within a target cell or tissue, one or more payload moieties (e.g., a therapeutic agent or imaging agent), and two or more non-interfering moieties covalently bound to the silicon-heteroatom core.

  本文描述了基于硅的共轭物，能够将一个或多个有效载荷基团传递到靶细胞或组织。考虑到的共轭物可能包括一个硅-杂原子核心，一个或多个可选的催化基团，一个定位基团，允许共轭物在靶细胞或组织内积累，一个或多个有效载荷基团（例如，治疗剂或成像剂），以及与硅-杂原子核心共价结合的两个或更多个不干扰基团。
• Thermally activated delayed fluorescent material based on 9,10-dihydro-9,9-dimethylacridine analogues for prolonging device longevity
  申请人：Arizona Board of Regents

  公开号：US11245078B2

  公开（公告）日：2022-02-08

  Thermally activated delayed fluorescent compounds and uses thereof are described. The thermally activated delayed fluorescent compounds are an analogues of 9,10-dihydro-9,9-dimethylacridine compounds.

  本文描述了热激活延迟荧光化合物及其用途。这些热激活延迟荧光化合物是9,10-二氢-9,9-二甲基蒽嗪化合物的类似物。
• OXADIAZOLE DERIVATIVE HAVING ENDOTHELIAL LIPASE INHIBITORY ACTIVITY
  申请人：Shionogi & Co., Ltd.

  公开号：EP2514749A1

  公开（公告）日：2012-10-24

  Disclosed is a compound which is useful as an endothelial lipase inhibitor. A compound represented by the formula: its pharmaceutically acceptable salt, or a solvate thereof, wherein Ring A is aromatic carbocycle or aromatic heterocycle, Z is -NR5-, -O- or -S-, R5 is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted aryl or the like, R1 is hydrogen, halogen, hydroxy, cyano, nitro, carboxy, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl or the like, R2 and R3 are each independently hydrogen, halogen, hydroxy or the like, R4 is a group represented by the formula: -(CR6R7)n-R8, wherein R6 and R7 are each independently hydrogen, halogen, hydroxy or the like, n is an integer of 0 to 3, R8 is carboxy, cyano, substituted or unsubstituted alkyl or the like, Rx is halogen, hydroxy, cyano, nitro, carboxy, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl or the like, m is an integer of 0 to 3.

  公开了一种可用作内皮脂肪酶抑制剂的化合物。 一种由式表示的化合物： 其药学上可接受的盐或其溶液、 其中 环 A 是芳香碳环或芳香杂环、 Z是-NR5-、-O-或-S-、 R5 是氢、取代或未取代的烷基、取代或未取代的烯基、取代或未取代的炔基、取代或未取代的芳基或类似物、 R1 是氢、卤素、羟基、氰基、硝基、羧基、取代或未取代的烷基、取代或未取代的烯基或类似物、 R2 和 R3 各自独立地为氢、卤素、羟基或类似物、 R4 是由式表示的基团：-(CR6R7)n-R8、 其中 R6 和 R7 各自独立地为氢、卤素、羟基或类似物，n 为 0 至 3 的整数，R8 为羧基、氰基、取代或未取代的烷基或类似物、 Rx 是卤素、羟基、氰基、硝基、羧基、取代或未取代的烷基、取代或未取代的烯基或类似物、 m 是 0 至 3 的整数。
• Thermally Activated Delayed Fluorescent Material Based on 9,10-Dihydro-9,9-dimethylacridine Analogues for Prolonging Device Longevity
  申请人：Arizona Board of Regents on behalf of Arizona State University

  公开号：US20170077420A1

  公开（公告）日：2017-03-16

  Thermally activated delayed fluorescent compounds and uses thereof are described. The thermally activated delayed fluorescent compounds are an analogues of 9,10-dihydro-9,9-dimethylacridine compounds.
• US8754113B2
  申请人：——

  公开号：US8754113B2

  公开（公告）日：2014-06-17